1.	Phase III Percutaneous Transfemoral Renal Artery Occlusion, Nephrectomy and Hormonal Therapy with Medroxyprogesterone Acetate for Metastatic Renal Carcinoma Phase: Phase III Type: Treatment Status: Closed Age: no age specified Sponsor: Protocol IDs: MDA-U/u17
2.	Phase III Provera (MPA) vs ADR vs ADR/CTX for Stage III/IV or Recurrent Endometrial Cancer Phase: Phase III Type: Treatment Status: Closed Age: no age specified Sponsor: NCI Protocol IDs: GOG-48, GOG-7941
3.	Phase III Postinfarction Nephrectomy plus Medroxyprogesterone Acetate for Metastatic Renal Cell Carcinoma Phase: Phase III Type: Treatment Status: Closed Age: no age specified Sponsor: NCI Protocol IDs: SWOG-7956
4.	Phase III Comparison of Immuneron vs Depo-Provera in Patients with Metastatic Renal Cell Carcinoma Phase: Phase III Type: Treatment Status: Closed Age: 18 to 75 Sponsor: Protocol IDs: BGSM-89285, NCI-V85-0243
5.	Phase III Randomized Comparison of Continuous vs Intermittent TMX vs Alternating TMX and MPA as First-Line Endocrine Therapy for Postmenopausal Patients with Advanced Carcinoma of the Breast Phase: Phase III Type: Treatment Status: Closed Age: postmenopausal Sponsor: Protocol IDs: EORTC-10863
6.	Phase III Randomized Study of Low-Dose vs High-Dose Medroxyprogesterone Acetate (Provera) in Patients with Advanced, Persistent, or Recurrent Endometrial Carcinoma Phase: Phase III Type: Treatment Status: Closed Age: no age specified Sponsor: NCI Protocol IDs: GOG-81
7.	Phase III Randomized Study of MPA with or without Continuation of Tamoxifen in Postmenopausal Patients with Advanced Breast Cancer that is Progressive on Tamoxifen (Summary Last Modified 09/90) Phase: Phase III Type: Treatment Status: Closed Age: postmenopausal Sponsor: Protocol IDs: COSA-ANZ-8613
8.	Phase II Hormone Therapy with MPA for Metastatic or Recurrent Breast Cancer Phase: Phase II Type: Treatment Status: Closed Age: no age specified Sponsor: Protocol IDs: MDA-MBDT-8111
9.	Phase II Hormone Therapy with Medroxyprogesterone Acetate in Postmenopausal Women with Refractory or Recurrent Metastatic Breast Cancer, ER-Positive or Unknown Phase: Phase II Type: Treatment Status: Closed Age: under 75 Sponsor: Protocol IDs: PCCC-80189, NCI-V83-0219
10.	Phase II Study of MPA for Recurrent Ovarian Carcinoma Phase: Phase II Type: Treatment Status: Closed Age: no age specified Sponsor: Protocol IDs: MAOP-7283
11.	Phase II Sequential Treatment with Ethinyl Estradiol and MPA for Metastatic and/or Recurrent Breast Cancer in Postmenopausal Women Phase: Phase II Type: Treatment Status: Completed Age: 75 and under Sponsor: Protocol IDs: PCCC-83239, NCI-V83-0354
12.	Phase II Master Protocol for Advanced, Recurrent Gynecologic Malignancies: Medroxyprogesterone for Epithelial Ovarian Cancer Resistant to Combination Chemotherapy Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: GOG-26R
13.	Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000306440, GOG-0211, NCT00064025
14.	Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: 0607-18 IUCRO-0154, TBCRC 007, NCT00577122
15.	Clinical Trial of Ridaforolimus Compared to Progestin or Chemotherapy for Advanced Endometrial Carcinoma (MK-8669-007 AM6) Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: MK-8669-007, AP23573-07-205, NCT00739830
16.	Hormonal Therapy with Aminoglutethimide and Hydrocortisone and Adrenalectomy for Breast Carcinoma Phase: No phase specified Type: Treatment Status: Closed Age: no age specified Sponsor: Protocol IDs: BCTF-4
17.	Induction and Maintenance Chemotherapy with Yoshi 864 plus Hormone Therapy with MPA for Adenocarcinoma of the Kidney in Adults Phase: No phase specified Type: Treatment Status: Closed Age: 16 to 80 Sponsor: NCI Protocol IDs: SWOG-7805
18.	Tamoxifen and Medroxyprogesterone Acetate for Disseminated Renal Cell Carcinoma Phase: No phase specified Type: Treatment Status: Closed Age: no age specified Sponsor: Protocol IDs: UMCC-7817
19.	Phase II Medroxyprogesterone Acetate for Recurrent Breast Cancer in Postmenopausal Women Phase: No phase specified Type: Treatment Status: Closed Age: 75 and under Sponsor: Protocol IDs: NCOG-1B811
20.	Master Protocol for Chemotherapy of Metastatic Ovarian Carcinoma and Hormone Therapy with Medroxyprogesterone Acetate Phase: No phase specified Type: Treatment Status: Closed Age: no age specified Sponsor: NCI Protocol IDs: EST-1876
21.	Master Protocol and Chemotherapy with MPA vs VP-16 and MGBG vs Phenestrin for Advanced Ovarian Cancer Phase: No phase specified Type: Treatment Status: Closed Age: no age specified Sponsor: NCI Protocol IDs: EST-2877
22.	Relation of Progestin Receptor Concentration to Efficacy of Progestin Therapy for Endometrial Adenocarcinoma - Pilot Study Phase: No phase specified Type: Treatment Status: Closed Age: no age specified Sponsor: NCI Protocol IDs: GOG-P12
23.	Radiotherapy plus Endocrine Therapy with Progestin for Stage III and Stage IV Adenocarcinoma of the Endometrium Phase: No phase specified Type: Treatment Status: Completed Age: no age specified Sponsor: NCI Protocol IDs: GOG-17